FibroBiologics, Inc. (FBLG)

FibroBiologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	9.24	9.23	6.52	3.32	1.06
Research & Development	7.41	4.5	2.37	1.15	0.52
Operating Expenses	16.65	13.74	8.89	4.47	1.58
Operating Income	-16.65	-13.74	-8.89	-4.47	-1.58
Interest Expense	-0.2	-0.02	-0.15	-0.65	-0
Interest & Investment Income	0.25	0.25	-	-	-
Other Non Operating Income (Expenses)	-2.04	2.35	-7.45	-	-
Pretax Income	-18.65	-11.16	-16.49	-5.12	-1.58
Net Income	-18.65	-11.16	-16.49	-5.12	-1.58
Preferred Dividends & Other Adjustments	-	-	2.57	-	-
Net Income to Common	-18.65	-11.16	-19.06	-5.12	-1.58
Shares Outstanding (Basic)	45	33	28	28	9
Shares Outstanding (Diluted)	45	33	28	28	9
Shares Change (YoY)	35.85%	16.45%	-	222.64%	-
EPS (Basic)	-0.42	-0.34	-0.68	-0.18	-0.18
EPS (Diluted)	-0.42	-0.34	-0.68	-0.18	-0.18
Free Cash Flow	-16.66	-12.09	-6.9	-4.07	-1.41
Free Cash Flow Per Share	-0.37	-0.37	-0.24	-0.14	-0.16
EBITDA	-16.41	-13.58	-8.84	-	-
D&A For EBITDA	0.24	0.16	0.05	-	-
EBIT	-16.65	-13.74	-8.89	-4.47	-1.58

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q